This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stearne, L. E. T.
Right arrow Articles by Gyssens, I. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stearne, L. E. T.
Right arrow Articles by Gyssens, I. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 243-251, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.243-251.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activity of Trovafloxacin against Bacteroides fragilis in Mixed Culture with either Escherichia coli or a Vancomycin- Resistant Strain of Enterococcus faecium Determined by an Anaerobic Time-Kill Technique

Lorna E. T. Stearne,* Clarissa Kooi, Wil H. F. Goessens, Irma A. J. M. Bakker-Woudenberg, and Inge C. Gyssens

Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands

Received 26 June 2000/Returned for modification 26 August 2000/Accepted 25 October 2000

To determine the efficacy of trovafloxacin as a possible treatment for intra-abdominal abscesses, we have developed an anaerobic time-kill technique using different inocula to study the in vitro killing of Bacteroides fragilis in pure culture or in mixed culture with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium (VREF). With inocula of 5 × 105 CFU/ml and trovafloxacin concentrations of <= 2 µg/ml, a maximum observed effect (Emax) of >= 6.1 (log10 CFU/ml) was attained with all pure and mixed cultures within 24 h. With inocula of 108 CFU/ml, a similar Emax and a similar concentration to produce 50% of Emax (EC50) for B. fragilis were found in both pure cultures and mixed cultures with E. coli. However, to produce a similar killing of B. fragilis in the mixed cultures with VREF, a 14-fold increase in the concentration of trovafloxacin was required. A vancomycin-susceptible strain of E. faecium and a trovafloxacin-resistant strain of E. coli were also found to confer a similar "protective" effect on B. fragilis against the activity of trovafloxacin. Using inocula of 109 CFU/ml, the activity of trovafloxacin was retained for E. coli and B. fragilis and was negligible against VREF. We conclude that this is a useful technique to study the anaerobic killing of mixed cultures in vitro and may be of value in predicting the killing of mixed infections in vivo. The importance of using mixed cultures and not pure cultures is clearly shown by the difference in the killing of B. fragilis in the mixed cultures tested. Trovafloxacin will probably be ineffective in the treatment of infections involving large numbers of enterococci. However, due to its ability to retain activity against large cultures of B. fragilis and E. coli, trovafloxacin could be beneficial in the treatment of intra-abdominal abscesses.

* Corresponding author. Mailing address: Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. Phone: 31-01-4087665. Fax: 31-10-4089454. E-mail: stearne{at}kmic.fgg.eur.nl.

Antimicrobial Agents and Chemotherapy, January 2001, p. 243-251, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.243-251.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Stearne, L. E. T., Goessens, W. H. F., Mouton, J. W., Gyssens, I. C. (2007). Effect of Dosing and Dosing Frequency on the Efficacy of Ceftizoxime and the Emergence of Ceftizoxime Resistance during the Early Development of Murine Abscesses Caused by Bacteroides fragilis and Enterobacter cloacae Mixed Infection. Antimicrob. Agents Chemother. 51: 3605-3611 [Abstract] [Full Text]  
  • Valeria dos Santos, K., Diniz, C. G., Coutinho, S. C., Apolonio, A. C. M., Geralda de Sousa-Gaia, L., Nicoli, J. R., Farias, L. d. M., Roque de Carvalho, M. A. (2007). In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures. J Med Microbiol 56: 798-802 [Abstract] [Full Text]  
  • Stearne, L. E. T., Vonk, A. G., Kullberg, B. J., Gyssens, I. C. (2005). Effect of Recombinant Murine Granulocyte Colony-Stimulating Factor with or without Fluoroquinolone Therapy on Mixed-Infection Abscesses in Mice. Antimicrob. Agents Chemother. 49: 3668-3675 [Abstract] [Full Text]  
  • Schaumann, R., Goldstein, E. J., Forberg, J., Rodloff, A. C (2005). Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 54: 749-753 [Abstract] [Full Text]  
  • Mizunaga, S., Kamiyama, T., Fukuda, Y., Takahata, M., Mitsuyama, J. (2005). Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems. J Antimicrob Chemother 56: 91-96 [Abstract] [Full Text]  
  • Hermsen, E. D., Hovde, L. B., Sprandel, K. A., Rodvold, K. A., Rotschafer, J. C. (2005). Levofloxacin plus Metronidazole Administered Once Daily versus Moxifloxacin Monotherapy against a Mixed Infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 49: 685-689 [Abstract] [Full Text]  
  • Stearne, L. E. T., van Boxtel, D., Lemmens, N., Goessens, W. H. F., Mouton, J. W., Gyssens, I. C. (2004). Comparative Study of the Effects of Ceftizoxime, Piperacillin, and Piperacillin-Tazobactam Concentrations on Antibacterial Activity and Selection of Antibiotic-Resistant Mutants of Enterobacter cloacae and Bacteroides fragilis In Vitro and In Vivo in Mixed-Infection Abscesses. Antimicrob. Agents Chemother. 48: 1688-1698 [Abstract] [Full Text]  
  • Stearne, L. E. T., Buijk, S. L., Mouton, J. W., Gyssens, I. C. (2002). Effect of a Single Percutaneous Abscess Drainage Puncture and Imipenem Therapy, Alone or in Combination, in Treatment of Mixed-Infection Abscesses in Mice. Antimicrob. Agents Chemother. 46: 3712-3718 [Abstract] [Full Text]  
  • Stearne, L. E. T., Gyssens, I. C., Goessens, W. H. F., Mouton, J. W., Oyen, W. J. G., van der Meer, J. W. M., Verbrugh, H. A. (2001). In Vivo Efficacy of Trovafloxacin against Bacteroides fragilis in Mixed Infection with either Escherichia coli or a Vancomycin-Resistant Strain of Enterococcus faecium in an Established-Abscess Murine Model. Antimicrob. Agents Chemother. 45: 1394-1401 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»